Akeso (HKSE:09926) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 09, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Akeso's float shares is 0.00 Mil. Akeso's total shares outstanding is 865.86 Mil. Akeso's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Akeso's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Akeso's Institutional Ownership is 18.99%.

Akeso Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Akeso's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	865.86
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Executives

Xia Yu	2501 Other
Wang Zhongmin Maxwell	2501 Other
Li Baiyong	2501 Other
Green Court Capital Holdings Limited	2201 Interest of corporation controlled by you
Green Court Capital Management Limited	2102 Investment manager
Green Court Management Holdings Llc	2201 Interest of corporation controlled by you
Yao Yulin	2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd.	2201 Interest of corporation controlled by you
Xia Yu	2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited	2301 Trustee
Aquae Hyperion Limited	2101 Beneficial owner
Htkf Investments Limited	2101 Beneficial owner

Akeso (HKSE:09926) Headlines

No Headlines